Search
Eptifibatide
go.drugbank.com/drugs/DB00063ApprovedInvestigationalSynthetic cyclic hexapeptide that binds to platelet receptor glycoprotein and inhibits platelet aggregation. Derived from venom of the Southeastern pygmy rattlesnake (Sistrurus miliarus barbouri), eptifibatide is a cyclic heptapeptide th...
Roxithromycin
go.drugbank.com/drugs/DB00778ApprovedInvestigationalWithdrawnIt is marketed in Australia as a treatment for respiratory tract, urinary and soft tissue infections.
International brands: Le Er Tai, Ren SuAtamparib
go.drugbank.com/drugs/DB19028InvestigationalAtamparib is under investigation in clinical trial NCT05127590 (RBN-2397 in Combination With Pembrolizumab in Patients With SCCL).
Bifenthrin
go.drugbank.com/drugs/DB15056ExperimentalBifenthrin is under investigation in clinical trial NCT01560247 (Percutaneous Recanalization in Ischemic Stroke Management in Europe Observational Registry).
SYNB1353
go.drugbank.com/drugs/DB17666InvestigationalSYNB1353 is a strain of the probiotic bacteria _Escherichia coli_ (_E. coli_) type Nissle and an engineered probiotic drug. … It is designed to consume methionine in the gastrointestinal tract to prevent its absorption and conversion into homocysteine.[L45983]
Amolimogene bepiplasmid
go.drugbank.com/drugs/DB04904InvestigationalAmolimogene is an investigational therapeutic designed to specifically augment the body's defensive response to human papillomavirus (HPV).
Tersolisib
go.drugbank.com/drugs/DB21752InvestigationalSTX-478 is under investigation in clinical trail NCT05768139 (First-in-Human Study of STX-478 as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
Necuparanib
go.drugbank.com/drugs/DB16251InvestigationalNecuparanib is under investigation in clinical trial NCT01621243 (M402 in Combination With Nab-paclitaxel and Gemcitabine in Pancreatic Cancer).
ABX-196
go.drugbank.com/drugs/DB16339InvestigationalABX-196 is under investigation in clinical trial NCT03897543 (ABX196 in Combination With Nivolumab in Patients With Hepatocellular Carcinoma).